Recently, a SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium collaborative meta-analysis revealed SGLT2i to be associated with a 9% reduction in MACE, driven primarily by reductions in CV deaths, particularly from HF and sudden cardiac death (Fig. 12).292, 293, 294, 295, 296, 297, 298, 299 These benefits are consistent across subgroups, including those with or without atherosclerotic CVD, diabetes, HF, and across a broad range of kidney functions. Here, SLC5A2 is linked to hydrops fetalis.